PROQR THERAPEUTICS EO-04 (0PQ) - Total Assets
Based on the latest financial reports, PROQR THERAPEUTICS EO-04 (0PQ) holds total assets worth €112.76 Million EUR (≈ $131.82 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore PROQR THERAPEUTICS EO-04 (0PQ) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
PROQR THERAPEUTICS EO-04 - Total Assets Trend (2021–2025)
This chart illustrates how PROQR THERAPEUTICS EO-04's total assets have evolved over time, based on quarterly financial data. See net assets of PROQR THERAPEUTICS EO-04 for net asset value and shareholders' equity analysis.
PROQR THERAPEUTICS EO-04 - Asset Composition Analysis
Current Asset Composition (December 2025)
PROQR THERAPEUTICS EO-04's total assets of €112.76 Million consist of 88.8% current assets and 11.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 82.0% |
| Accounts Receivable | €3.36 Million | 3.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how PROQR THERAPEUTICS EO-04's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PROQR THERAPEUTICS EO-04 stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PROQR THERAPEUTICS EO-04's current assets represent 88.8% of total assets in 2025, a decrease from 91.4% in 2021.
- Cash Position: Cash and equivalents constituted 82.0% of total assets in 2025, down from 89.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 3.0% of total assets.
PROQR THERAPEUTICS EO-04 Competitors by Total Assets
Key competitors of PROQR THERAPEUTICS EO-04 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
PROQR THERAPEUTICS EO-04 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.09 | 3.95 | 2.33 |
| Quick Ratio | 3.09 | 3.95 | 2.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €67.69 Million | €114.94 Million | €52.77 Million |
PROQR THERAPEUTICS EO-04 - Advanced Valuation Insights
This section examines the relationship between PROQR THERAPEUTICS EO-04's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.88 |
| Latest Market Cap to Assets Ratio | 1.26 |
| Asset Growth Rate (YoY) | -32.9% |
| Total Assets | €112.76 Million |
| Market Capitalization | $142.34 Million USD |
Valuation Analysis
Above Book Valuation: The market values PROQR THERAPEUTICS EO-04's assets above their book value (1.26x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: PROQR THERAPEUTICS EO-04's assets decreased by 32.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PROQR THERAPEUTICS EO-04 (2021–2025)
The table below shows the annual total assets of PROQR THERAPEUTICS EO-04 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €112.76 Million ≈ $131.82 Million |
-32.87% |
| 2024-12-31 | €167.96 Million ≈ $196.36 Million |
+21.81% |
| 2023-12-31 | €137.88 Million ≈ $161.20 Million |
-19.52% |
| 2022-12-31 | €171.32 Million ≈ $200.29 Million |
-18.25% |
| 2021-12-31 | €209.58 Million ≈ $245.02 Million |
-- |
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more